http://ift.tt/eA8V8J
CARLSBAD, Calif.–(BUSINESS WIRE)–GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the upsizing and pricing of its previously announced underwritten public offering of 6,382,978 shares of its common stock at a public offering price of $11.75 per share. The gross proceeds to GenMark, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximatel
June 14, 2017 at 05:01AM
from
No comments:
Post a Comment